Navigation Links
New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment
Date:12/15/2007

SAN ANTONIO, Dec. 15 /PRNewswire/ -- Denosumab is a new drug being studied to prevent fractures in breast cancer patients receiving hormonal therapy. Results of a phase 3 clinical trial using denosumab were presented Friday evening at the San Antonio Breast Cancer Symposium by Georgiana Ellis, MD, from the Seattle Cancer Care Alliance.

Denosumab is a highly specific antibody that interrupts the development of osteoclasts -- specialized cells that break down bone. Because it is highly specific, the chance of systemic effects in other parts of the body is low, so patients do not need routine laboratory monitoring.

A group of drugs called aromatase inhibitors is used to prevent the recurrence of breast cancer in postmenopausal women. These drugs are very effective, but commonly associated with loss of bone density and an increased risk of fractures.

To test the effectiveness of denosumab in preventing bone loss caused by aromatase inhibitors, a clinical trial recruited 252 patients who had been treated for early stage breast cancer and for whom treatment with anastrozole, an aromatase inhibitor, was planned. Half of the patients were given denosumab, while the other half was not. All patients were instructed to take daily doses of calcium and vitamin D.

The study lasted for 2 years, with patients receiving an injection of denosumab every 6 months. All the women from both groups had their lumbar spine bone density measured at the end of the first and second years. By the end of the first year, the bone density of the women receiving denosumab had increased by nearly 5%, while the women who did not receive denosumab had bone density decreases of almost 1%. By the end of the second year, the difference was even greater: in the women receiving denosumab, bone density had increased by almost 6%, while the bone density of the women who did not receive denosumab decreased by nearly 2%. Similar effects on bone density were seen at the hip and
'/>"/>

SOURCE San Antonio Breast Cancer Symposium
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Flash Technology Prevents Pain From Carpal Tunnel Syndrome
2. International Atomic Energy Agency and National Foundation for Cancer Research Launch Major Initiative to Improve Cancer Prevention and Treatments in Developing Countries
3. New White Paper Details Six Steps to Investigate and Prevent Laboratory Accidents
4. Protherics UK Ltd. Chooses TrackWise for Corrective Action and Preventive Action (CAPA) Management
5. Leading Edge Research Underway in Fall Prevention for Seniors
6. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
7. Individual differences caused by shuffled chunks of DNA in the human genome
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
10. Imaging Diagnostic Systems New Laser Breast Imaging Scanner Introduced in Malaysia
11. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/17/2010)... , ... Offers Online Promotions – Discounts on Stereomicroscopy and Converting to 3D Imaging , ... Thornwood, N.Y. (PRWEB) March ... a variety of research, clinical and industrial applications, recently announced two exciting online promotions. ...
(Date:3/17/2010)... ... leading provider of next generation business intelligence software, today announced the availability of Centrifuge ... , ... March 17, 2010 -- Centrifuge Systems, Inc. , a leading provider of next ...
(Date:3/16/2010)... , TAMPA, Fla. (March 16, 2010)Approximately half of Americans ... some point during the course of their disease. Radiofrequency ... in the tumor causing cancer cell death with minimal ... prolongation of their life by nearly three years, note ...
(Date:3/16/2010)... Fe, NM, USA -- March 12, 2010A Materials Design client ... of the General Motors R&D Center, has been honored with ... , Fundamentals of Interfacial Tribology, Multi-scale Modeling of High-temperature Deformation ... honor of John M. Campbell, a former scientific director of ...
Breaking Biology Technology:Carl Zeiss Offers Online Promotions 2Centrifuge Releases New Data Visualization Software 2Centrifuge Releases New Data Visualization Software 3Living longer: Colon cancer patients gain time with radiofrequency ablation treatment 2Living longer: Colon cancer patients gain time with radiofrequency ablation treatment 3
... Poniard,Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... McMahon, Ph.D.,chairman and CEO, will present at the 11th ... 10, at 10 a.m. Eastern Time at the,Waldorf-Astoria in ... will provide a corporate overview, including a discussion of,the ...
... Shares of Common StockAt a Price of $5.00 per ... Group, Inc. (the "Company" or "PharmaNet") (Nasdaq: ... today announced that it has signed a definitive merger ... ("JLL"). Under the terms of the Merger Agreement, JLL ...
... Corporation,(Nasdaq: DNDN ) today announced that management will ... Investor Conference in New York City, on,Tuesday, February 10, 2009 ... live audio webcast of the presentation will be accessible through ... you are unable to listen to the live webcast, it ...
Other Biology Technology:Poniard Pharmaceuticals to Present at the BIO CEO & Investor Conference 2PharmaNet Development Group Agrees to be Acquired by JLL Partners 2PharmaNet Development Group Agrees to be Acquired by JLL Partners 3PharmaNet Development Group Agrees to be Acquired by JLL Partners 4PharmaNet Development Group Agrees to be Acquired by JLL Partners 5PharmaNet Development Group Agrees to be Acquired by JLL Partners 6PharmaNet Development Group Agrees to be Acquired by JLL Partners 7
(Date:3/17/2010)... press conferences will take place during the March Meeting of ... 2010 in the Portland Convention Center. Journalists are invited to ... found at the end of this release. , MONDAY ... (session B2) , This briefing highlights one of the most ...
(Date:3/17/2010)... Tourists wanting to watch and swim with dolphins are now ... protect both the animals and the local communities whose livelihoods ... off the coast of Zanzibar has found that the many ... preventing them from resting, feeding and nurturing their young. , ...
(Date:3/17/2010)... of Chicago scientists have successfully used geometrically patterned surfaces ... approach is a departure from that of many stem-cell ... proteins in controlling the fate of stem cells. , ... both cases it,s the shape alone that,s dictating whether ...
Breaking Biology News(10 mins):Physics press conferences at next week's American Physical Society March Meeting 2Physics press conferences at next week's American Physical Society March Meeting 3Physics press conferences at next week's American Physical Society March Meeting 4Physics press conferences at next week's American Physical Society March Meeting 5Physics press conferences at next week's American Physical Society March Meeting 6Physics press conferences at next week's American Physical Society March Meeting 7Physics press conferences at next week's American Physical Society March Meeting 8Physics press conferences at next week's American Physical Society March Meeting 9Physics press conferences at next week's American Physical Society March Meeting 10Physics press conferences at next week's American Physical Society March Meeting 11Physics press conferences at next week's American Physical Society March Meeting 12Thrill-seeking holiday-makers are putting dolphins at risk 2Encorium Re Appoints Dr Kai Lindevall as Chief Executive Officer and Appoints Current Director Shahab Fatheazam Chairman of the Board 7367 1Encorium Re Appoints Dr Kai Lindevall as Chief Executive Officer and Appoints Current Director Shahab Fatheazam Chairman of the Board 7367 2Encorium Re Appoints Dr Kai Lindevall as Chief Executive Officer and Appoints Current Director Shahab Fatheazam Chairman of the Board 7367 3Encorium Re Appoints Dr Kai Lindevall as Chief Executive Officer and Appoints Current Director Shahab Fatheazam Chairman of the Board 7367 4Encorium Re Appoints Dr Kai Lindevall as Chief Executive Officer and Appoints Current Director Shahab Fatheazam Chairman of the Board 7367 5Encorium Re Appoints Dr Kai Lindevall as Chief Executive Officer and Appoints Current Director Shahab Fatheazam Chairman of the Board 7367 6Insulated Transport Containers Go Green 64546 1Insulated Transport Containers Go Green 64546 2QualiSystems TestShell now Maximizes Test Lab Resource Management 7364 1QualiSystems TestShell now Maximizes Test Lab Resource Management 7364 2QualiSystems TestShell now Maximizes Test Lab Resource Management 7364 3
... As part of the ongoing mission to train and ... in genomics, the J. Craig Venter Institute,s (JCVI) Eukaryotic ... TX March 3rd-5th to train 40 United States Agriculture ... , The training session will focus on the use ...
... University of Pennsylvania team has completed the first successful ... blood flow in patients with acute stroke, a leading ... of this research is to improve the management of ... continuous bedside monitoring of brain blood flow and metabolism. ...
... country will convene on the University of Houston for a ... issues and intervention strategies. , The UH Texas ... 10 at the UH M.D. Anderson Library, Rockwell Pavilion. ... and have high hopes that others will see the wealth ...
Other Biology News:JCVI program trains USDA scientists on eukaryotic genome analysis 2Penn research team tests bedside monitoring of brain blood flow and metabolism in stroke victims 2Texas Obesity Research Center at UH assembles researchers to discuss obesity 2
Conjugate Quality Control Evaluation Specificity: Conjugate Quality Control Evaluation ...
Qa-1 (L-12)...
... This Kit Contains the following: , Coated ... plate sealers , Wash/Sample Diluent: 300 mL of ... 1 vial 10 microg lyophilized peptide , Lyophilized ... microL of 50X concentrate , Secondary Antibody-HRP: 30 ...
Peptide Sequence: ovine COX-1 amino acids 272-282 (LMHYPRGIPPQ) To be used in conjunction with Cayman's COX-1 (ovine) polyclonal antiserum (Catalog No. 160108) to block protein-antibody complex f...
Biology Products: